4.4 Article

Sedative and hypothermic effects of γ-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: Assessment using biotelemetry

Journal

DRUG AND ALCOHOL DEPENDENCE
Volume 103, Issue 3, Pages 137-147

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2009.03.004

Keywords

gamma-Hydroxybutyrate (GHB); 3,4-Methylenedioxymethamphetamine; (MDMA); Methamphetamine (METH); Telemetry; Body temperature; Locomotor activity

Funding

  1. NHMRC

Ask authors/readers for more resources

The recreational drug gamma-hydroxybutyrate (GHB) has euphoric effects and can induce sedation and body temperature changes. GHB is frequently combined with other recreational drugs although these interactions are not well characterised. The present study used biotelemetry to provide a fine-grained analysis of the effects of GHB oil body temperature and locomotor activity in freely moving rats, and investigated interactions between GHB and 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (METH) and various antagonist drugs. GHB (1000 mg/kg) caused profound sedation for more than 2 h and a complex triphasic effect on body temperature: an initial hypothermia (5-40 min), followed by hyperthermia (40-140 min), followed again by hypothermia (140-360 min). A lower GHB close (500 mg/kg) also Caused sedation but Only a hypothermic effect that lasted up to 6 h. The dopamine D-1 receptor antagonist SCH 23390 (1 mg/kg), the opioid antagonist naltrexone (1 mg/kg), the benzodiazepine antagonist flumazenil (10 mg/kg), and the 5-HT2A/2C receptor antagonist ritanserin (1 mg/kg) did not prevent the overall sedative or body temperature effects of GHB (1000 mg/kg). However the GABA(B) antagonist SCH 50911 (50 mg/kg) prevented the hyperthermia induced by GHB (1000 mg/kg). Repeated daily administration of GHB (1000 mg/kg) produced tolerance to the sedative and hyperthermic effects of the drug and cross-tolerance to the sedative effects of the GABA(B) receptor agonist baclofen (10 mg/kg). A high ambient temperature of 28 degrees C prevented the hypothermia obtained with GHB (500 mg/kg) at 20 degrees C, while GHB (500 mg/kg) reduced the hyperthermia and hyperactivity produced by co-administered doses of MDMA (5 mg/kg) or METH (1 mg/kg) at 28 degrees C. These results further confirm a role for GABA(B) receptors in the hypothermic and sedative effects of GHB and show an interaction between GHB and MDMA, and GHB and METH, that may be relevant to the experience of recreational users Who mix these drugs. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Anastasia Suraev, Ronald R. Grunstein, Nathaniel S. Marshall, Angela L. D'Rozario, Christopher J. Gordon, Delwyn J. Bartlett, Keith Wong, Brendon J. Yee, Ryan Vandrey, Chris Irwin, Jonathon C. Arnold, Iain S. McGregor, Camilla M. Hoyos

BMJ OPEN (2020)

Article Oncology

Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial

P. Grimison, A. Mersiades, A. Kirby, N. Lintzeris, R. Morton, P. Haber, I Olver, A. Walsh, I McGregor, Y. Cheung, A. Tognela, C. Hahn, K. Briscoe, M. Aghmesheh, P. Fox, E. Abdi, S. Clarke, S. Della-Fiorentina, J. Shannon, C. Gedye, S. Begbie, J. Simes, M. Stockler

ANNALS OF ONCOLOGY (2020)

Article Pharmacology & Pharmacy

Interactions between cannabidiol and Δ9-tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome

Lyndsey L. Anderson, Ivan K. Low, Iain S. McGregor, Jonathon C. Arnold

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Article Clinical Neurology

The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol

Danielle McCartney, Melissa J. Benson, Anastasia S. Suraev, Christopher Irwin, Thomas R. Arkell, Ronald R. Grunstein, Camilla M. Hoyos, Iain S. McGregor

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2020)

Article Behavioral Sciences

In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018

Thomas F. Gamage, Daniel G. Barrus, Richard C. Kevin, David B. Finlay, Timothy W. Lefever, Purvi R. Patel, Megan A. Grabenauer, Michelle Glass, Iain S. McGregor, Jenny L. Wiley, Brian F. Thomas

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2020)

Article Substance Abuse

Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial

Nicholas Lintzeris, Llewellyn Mills, Adrian Dunlop, Jan Copeland, Iain Mcgregor, Raimondo Bruno, Adrienne Kirby, Mark Montebello, Michelle Hall, Meryem Jefferies, Richard Kevin, Anjali Bhardwaj

DRUG AND ALCOHOL DEPENDENCE (2020)

Article Clinical Neurology

The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial

Danielle McCartney, Ashling D. Isik, Kieron Rooney, Jonathon C. Arnold, Delwyn J. Bartlett, Bridin Murnion, Elisha Richards, Thomas R. Arkell, Nicholas Lintzeris, Iain S. McGregor

Summary: During cannabis withdrawal, moderate-intensity aerobic exercise may help alleviate sleep disturbances. Cycling exercise can improve sleep duration and efficiency compared to the control stretching routine.

JOURNAL OF SLEEP RESEARCH (2021)

Article Multidisciplinary Sciences

The effect of COVID19 pandemic restrictions on an urban rodent population

Miguel A. Bedoya-Perez, Michael P. Ward, Max Loomes, Iain S. McGregor, Mathew S. Crowther

Summary: The study found that during the COVID-19 lockdown period, both rodent captures and activity increased in the City of Sydney, Australia, while there was no significant change in complaint frequency. It is hypothesized that rodents redistributed in response to resource scarcity. These findings suggest that the onset of COVID-19 may have disrupted commensal rodent populations, with potential implications for future management.

SCIENTIFIC REPORTS (2021)

Article Biochemistry & Molecular Biology

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials

Thomas R. Arkell, Richard C. Kevin, Frederick Vinckenbosch, Nicholas Lintzeris, Eef Theunissen, Johannes G. Ramaekers, Iain S. McGregor

Summary: The study found that males performed better on a divided attention task and had higher peak plasma concentrations of 11-COOH-THC compared to females, but there were no significant differences between sexes in subjective drug effects and cardiovascular measures regarding cannabis effects.

ADDICTION BIOLOGY (2022)

Article Critical Care Medicine

Cannabinoids, Insomnia, and Other Sleep Disorders

Isobel Lavender, Iain S. McGregor, Anastasia Suraev, Ronald R. Grunstein, Camilla M. Hoyos

Summary: Sleep disturbances have been cited as a common reason for using medicinal cannabis, and there is increasing clinical interest in its potential in treating sleep disorders. However, the current evidence is limited by small sample sizes, lack of controlled study designs, and high risk of bias. This review summarizes the current evidence and discusses practical considerations for clinicians regarding the use of cannabinoids for sleep disorders.

CHEST (2022)

Review Medicine, Research & Experimental

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Jonathon C. Arnold, Danielle McCartney, Anastasia Suraev, Iain S. McGregor

Summary: Global interest in CBD is increasing, with clinical trial evidence supporting high doses for treating childhood epilepsies. However, the therapeutic benefits of low-dose CBD products are still being debated. This review evaluated the efficacy and safety of low oral doses of CBD and found that doses of 300 mg or higher showed evidence of reducing anxiety and anti-addiction effects, but the effects on insomnia, neurological disorders, and chronic pain were limited and inconsistent.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Pharmacology & Pharmacy

A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis

Zeeta Bawa, Bandana Saini, Danielle McCartney, Miguel Bedoya-Perez, Andrew J. McLachlan, Iain S. McGregor

Summary: This study examined Australian pharmacists' experience, knowledge, and attitudes towards medicinal cannabis and low-dose cannabidiol products supplied without a prescription. The results showed that pharmacists supported improved access to cannabis products but highlighted the need for better training and education in this area.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2023)

Article Substance Abuse

Access to cannabidiol without a prescription: A cross-country comparison and analysis

Iain S. McGregor, Elizabeth A. Cairns, Sarah Abelev, Rhys Cohen, Mat Henderson, Daniel Couch, Jonathon C. Arnold, Natalie Gauld

INTERNATIONAL JOURNAL OF DRUG POLICY (2020)

Review Sport Sciences

Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

Danielle McCartney, Melissa J. Benson, Ben Desbrow, Christopher Irwin, Anastasia Suraev, Iain S. McGregor

SPORTS MEDICINE-OPEN (2020)

Article Substance Abuse

Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)

Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, Maria Bravo, Thomas Arkell, Jonathon C. Arnold, Melissa J. Benson, Iain S. McGregor

HARM REDUCTION JOURNAL (2020)

No Data Available